skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Refametinib (Code C74059)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Refametinib

Definition: An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

Display Name: Refametinib

Label: Refametinib

NCI Thesaurus Code: C74059 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2346909  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BAY 869766
MEK Inhibitor RDEA119

External Source Codes: 
CAS Registry Number 923032-37-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 589128
PDQ Open Trial Search ID 589128 (check for NCI PDQ open clinical trial info)
UMLS CUI C2346909

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C19H20F3IN2O5S
code C74059
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name MEK_Inhibitor_RDEA119
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom